KRAS and cancer: On the other hand, a review on the pharmacogenomics of the KRAS gene was recently published, in which the authors explain the incidence of the different mutations of this gene for 7 types of cancer, revealing an approximate mutation frequency of 45% in the United States and 49% in China of CRC cases.